Long Term Safety Study of PRALUENT

Stopped The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.

Conditions

• Heterozygous Familial Hypercholesterolemia
• Non-familial Hypercholesterolemia

Interventions

• DRUG: Praluent

Sponsor

Regeneron Pharmaceuticals

Collaborators

• [object Object]